Our Proprietary Delivery Platforms
Ractigen Therapeutics values the importance of delivery technologies. We have created our own in-house platforms that strengthen our IP portfolio and enable drug development of our oligonucleotide therapies. Our Smart Chemistry-Aided Delivery (SCAD™) technology unlocks access to extrahepatic tissues (e.g., CNS), while our GaINAc-Oligonucleotide Liver Delivery (GOLD™) platform utilizes new innovations in linker chemistry for liver-targeted delivery.
Our SCAD™ System
Smart Chemistry-Aided Delivery (SCAD™)
Ractigen boasts the creation of a breakthrough platform technology for extrahepatic delivery of duplex RNAs termed Smart Chemistry-Aided Delivery (SCAD™).
By judicious use of chemical modifications, our proprietary SCAD™ system endows duplex RNA with self-delivering properties including broad tissue biodistribution and durable activity otherwise not previously possible with oligonucleotides.
Manufacturing is compatible with classic oligonucleotide synthesis in which the entire process is performed on-support using amidite chemistry. SCAD™ represents an innovative jump in delivery technologies unlocking the door to tissues and organs historically cutoff from oligonucleotide therapeutics.
Beside utilizing our SCAD™ technology to develop an internal pipeline of products, we seek to develop the broad potential of our SCAD™ platform through research collaborations and licensing agreements in multiple therapeutic applications. For more information, please contact us.
Our GOLD™ Platform
Leveraging SDL™ Technology
SDL™ (Smart Diverse Linker) is a versatile linker utilizing innovative chemistry for conjugating one or more targeting moieties to an oligonucleotide.
GaINAc-Oligonucleotide Liver Delivery (GOLD™)
By leveraging our SDL™ technology, Ractigen has created the GOLD™ platform that compares favorably with industry benchmarks for liver delivery of duplex RNA.